September 28, 2021 -- GenScript ProBio and AskGene have signed a nonexclusive licensing agreement covering the use of GenScript ProBio's single-domain antibody (sdAb) to target an immune checkpoint target.
Specifically, the license covers the sdAb immune checkpoint target for discovery, development, and commercialization of antibody and derivative products, according to the companies. In addition, GenScript ProBio will be AskGene's preferred partner for chemistry manufacturing, and control development, as well as clinical and commercial manufacturing of the product.
The sdAb will be paired with AskGene's cytokine therapeutics technology for cancer immunotherapy and other applications, the firms said.
Copyright © 2021 scienceboard.net